Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2025-12-26 @ 1:10 AM
Study NCT ID:
NCT03572634
Status:
TERMINATED
Last Update Posted:
2023-11-09
First Post:
2018-05-21
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
Sponsor:
Sumitomo Pharma America, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-06-10
Start Date Type:
ACTUAL
Primary Completion Date:
2020-01-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-01-21
Completion Date Type:
ACTUAL
First Submit Date:
2018-05-21
First Submit QC Date:
None
Study First Post Date:
2018-06-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2020-11-19
Results First Submit QC Date:
None
Results First Post Date:
2021-02-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-07
Last Update Post Date:
2023-11-09
Last Update Post Date Type:
ACTUAL